ECOG-ACRIN E1910
Proved that adding the immunotherapy blinatumomab to standard treatment saves lives even in patients whose leukaemia was already undetectable.
224 MRD-negative patients randomised. 3-year OS 85% vs 68% (HR 0.41, 95% CI 0.23-0.73); relapse-free survival 80% vs 64%. NEJM 2024. Basis for the June 2024 FDA approval of blinatumomab in consolidation regardless of MRD status; changed frontline adult ALL worldwide. Benefit persisted across age and MRD sensitivity.
- 85 vs 68 out of 100 alive at 3 years with Blinatumomab + chemotherapy compared with Chemotherapy; 17 more per 100.
- Roughly one extra person helped for every 6 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 59 percent lower chance of the event at any given time (hazard ratio 0.41, likely range 0.23 to 0.73).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- 80 vs 64 out of 100 alive without the cancer coming back at 3 years with Blinatumomab + chemotherapy compared with Chemotherapy; 16 more per 100.
- Roughly one extra person helped for every 6 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Newly diagnosed Ph-negative B-ALL, age 30-70, in MRD-negative remission after induction: blinatumomab added to consolidation chemotherapy vs chemotherapy alone. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
488 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival at 3 years (MRD-negative cohort)primary | Blinatumomab + chemotherapy | 112 | 85% | 0.41 (0.23–0.73) | 0.002 | link |
| Chemotherapy | 112 | 68% | ||||
| Relapse-free survival at 3 years | Blinatumomab + chemotherapy | — | 80% | — | — | — |
| Chemotherapy | — | 64% |
Pages like this
not linked directly; found by shared links- TrialTOWER
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific).
- TrialCOG AALL1731
Shares Blinatumomab added to frontline chemotherapy, Blinatumomab, CD3, CD19.
- Key paperChildren's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL
Shares Blinatumomab added to frontline chemotherapy, ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Blinatumomab, CD3.
- PersonRachel E. Rau
Shares Blinatumomab, CD19, Acute lymphoblastic leukaemia.
- IdeaTransplant-free Ph-positive ALL for MRD-negative adults
Shares MRD-negative complete remission, Blinatumomab, Acute lymphoblastic leukaemia.
- TrialD-ALBA (GIMEMA LAL2116)
Shares Blinatumomab, CD19, Acute lymphoblastic leukaemia.
- CompanyXencor
Shares CD3, T-cell engagers (bispecific).
- PersonJae H. Park
Shares CD19, Acute lymphoblastic leukaemia.